TENAYA
E827013
TENAYA is a Phase III clinical trial evaluating the efficacy and safety of faricimab for the treatment of neovascular (wet) age-related macular degeneration.
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
Phase III clinical trial
ⓘ
clinical trial ⓘ ophthalmology clinical trial ⓘ |
| allocation | randomized ⓘ |
| comparison | faricimab versus aflibercept ⓘ |
| conditionCategory | age-related macular degeneration ⓘ |
| controlTreatment | aflibercept NERFINISHED ⓘ |
| developerOfInvestigationalDrug |
Genentech
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| drugClass | bispecific antibody ⓘ |
| drugMechanism | dual inhibition of VEGF-A and Ang-2 ⓘ |
| drugTarget |
Angiopoietin-2
NERFINISHED
ⓘ
VEGF-A NERFINISHED ⓘ |
| evaluates | faricimab NERFINISHED ⓘ |
| evaluatesEfficacyOf | faricimab NERFINISHED ⓘ |
| evaluatesSafetyOf | faricimab NERFINISHED ⓘ |
| geographicScope | multinational ⓘ |
| indication |
neovascular age-related macular degeneration
ⓘ
wet age-related macular degeneration ⓘ |
| indicationAbbreviation | nAMD ⓘ |
| investigationalDrug | faricimab NERFINISHED ⓘ |
| masking | double-masked ⓘ |
| objective | to demonstrate non-inferiority of faricimab to aflibercept in nAMD ⓘ |
| outcomeMeasure |
anatomical retinal outcomes
ⓘ
safety and tolerability ⓘ visual acuity outcomes ⓘ |
| phase | Phase III ⓘ |
| population | adult patients ⓘ |
| primaryEndpoint | change in best-corrected visual acuity at one year ⓘ |
| primaryEndpointType | efficacy ⓘ |
| registrationDatabase | ClinicalTrials.gov NERFINISHED ⓘ |
| relatedTrial | LUCERNE NERFINISHED ⓘ |
| resultsSupport | approval of faricimab for nAMD in multiple regions ⓘ |
| routeOfAdministration | intravitreal injection ⓘ |
| secondaryEndpointType | safety ⓘ |
| sponsor |
Genentech
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| sponsorType | industry ⓘ |
| therapeuticArea |
ophthalmology
ⓘ
retinal disease ⓘ |
| treats |
neovascular age-related macular degeneration
ⓘ
wet age-related macular degeneration ⓘ |
| trialDesign |
active-controlled
ⓘ
double-masked ⓘ randomized ⓘ |
| trialStatus | completed ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.